Amylyx Pharmaceuticals Closes $135M Series C Financing Led by Viking Global Investors to Support Late Stage Development of Lead Product Candidate AMX0035 for the Treatment of ALS

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2V2fiKZ
via IFTTT